Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurence Booth

Showing results (31-40 of 92) with videos related to

Pageof 10
Sort By:
Frontiers in Oncology|July 6, 2016
Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor TherapeuticMehrad Tavallai, Laurence Booth, Jane L Roberts, et al.
Oncotarget|November 16, 2017
HDAC inhibitors enhance the immunotherapy response of melanoma cellsLaurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Cancer Biology & Therapy|November 4, 2018
Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibitionLaurence Booth, Jane L Roberts, Sarah Spiegel, et al.
Frontiers in Oncology|April 26, 2021
GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma CellsLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Journal of Cellular Physiology|January 18, 2020
GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacyLaurence Booth, Jane L Roberts, Cameron West, et al.
Journal of Cellular Physiology|January 28, 2020
(Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivoPaul Dent, Laurence Booth, Jane L Roberts, et al.
Cancer Biology & Therapy|August 7, 2013
PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cellsLaurence Booth, Nichola Cruickshanks, Thomas Ridder, et al.
Anti-Cancer Drugs|March 11, 2025
GZ17-6.02 interacts with carboplatin and etoposide to kill neuroblastoma cellsMichael R Booth, Laurence Booth, Jane L Roberts, et al.
Molecular Pharmacology|September 20, 2012
Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stressNichola Cruickshanks, Yong Tang, Laurence Booth, et al.
Frontiers in Oncology|September 7, 2021
GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 ProteinsLaurence Booth, Cameron West, Robert P Moore, et al.
Pageof 10

Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
Frontiers in Oncology|July 6, 2016
Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor TherapeuticMehrad Tavallai, Laurence Booth, Jane L Roberts, et al.
Oncotarget|November 16, 2017
HDAC inhibitors enhance the immunotherapy response of melanoma cellsLaurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Cancer Biology & Therapy|November 4, 2018
Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibitionLaurence Booth, Jane L Roberts, Sarah Spiegel, et al.
Frontiers in Oncology|April 26, 2021
GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma CellsLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Journal of Cellular Physiology|January 18, 2020
GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacyLaurence Booth, Jane L Roberts, Cameron West, et al.
Journal of Cellular Physiology|January 28, 2020
(Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivoPaul Dent, Laurence Booth, Jane L Roberts, et al.
Cancer Biology & Therapy|August 7, 2013
PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cellsLaurence Booth, Nichola Cruickshanks, Thomas Ridder, et al.
Anti-Cancer Drugs|March 11, 2025
GZ17-6.02 interacts with carboplatin and etoposide to kill neuroblastoma cellsMichael R Booth, Laurence Booth, Jane L Roberts, et al.
Molecular Pharmacology|September 20, 2012
Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stressNichola Cruickshanks, Yong Tang, Laurence Booth, et al.
Frontiers in Oncology|September 7, 2021
GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 ProteinsLaurence Booth, Cameron West, Robert P Moore, et al.
Pageof 10